Cellectis S.A. logo
Cellectis S.A. CLLS
$ 3.66 0.83%

Quarterly report 2025-Q4
added 05-11-2026

report update icon

Cellectis S.A. Balance Sheet 2011-2026 | CLLS

Annual Balance Sheet Cellectis S.A.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-26.1 M -101 M -85.3 M -36 M - -206 M -293 M -450 M -256 M -252 M -342 M -132 M -4.82 M -23.2 M 14.1 M

Long Term Debt

27.7 M 34.2 M 42.9 M 49.4 M - 28.8 M 46.5 M 1.02 M 13 K 29.4 K 2.19 K 3.38 M 4.23 M 4.37 M 67.5 M

Long Term Debt Current

7.7 M 8.38 M 8.5 M 7.87 M 8.33 M 6.7 M 1.07 M 333 K - - - - - - -

Total Non Current Liabilities

103 M 86.2 M 94.4 M 72.3 M - 109 M 49.4 M 3.7 M 3.44 M 589 K 550 K 3.92 M 5.26 M 5.06 M 67.9 M

Total Liabilities

249 M 253 M 250 M - - - 112 M 50.6 M 47 M 56.6 M 84.7 M 95 M 37.5 M 33.4 M 94.9 M

Deferred Revenue

- - - - - 452 K 20 M 20.8 M 26.1 M 38.8 M 59.9 M 72.3 M 7.75 M - -

Retained Earnings

- - - - - -506 M -406 M -327 M -252 M -166 M -150 M - - - -67.2 M

Total Assets

325 M 384 M 334 M 261 M 382 M 469 M 467 M 501 M 333 M 331 M 373 M 167 M 44.1 M 115 M 132 M

Cash and Cash Equivalents

61.5 M 143 M 137 M 93.2 M 186 M 241 M 341 M 452 M 256 M 255 M 342 M - - - -

Book Value

75.9 M 131 M 84.7 M 261 M 382 M 469 M 355 M 450 M 286 M 274 M 288 M 72.4 M 6.65 M 81.7 M 37 M

Total Shareholders Equity

75.9 M 131 M 84.7 M 126 M - 309 M 355 M 450 M 284 M 273 M 287 M - - - -

All numbers in USD currency

Quarterly Balance Sheet Cellectis S.A.

2025-Q4 2025-Q2 2024-Q4 2024-Q2 2023-Q4 2023-Q3 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

27.7 M 32.3 M 34.2 M 38.4 M 42.9 M - 46.2 M - - - - 71.5 M - 75.8 M - 75.8 M - 64.9 M - 46.5 M - - - 1.02 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

103 M 89.4 M 86.2 M 98.9 M 94.4 M 89.6 M 89.1 M - - - - 96.3 M - 104 M - 109 M - 74.6 M - 49.4 M - - - 3.7 M - - - 3.44 M - - - 590 K - - - 548 K - - - 3.91 M - - - - - - - - - - - - - - -

Total Liabilities

249 M 257 M 253 M 259 M 250 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - - - - - - - - - - - - -586 M - -506 M - -509 M - -406 M - - - -327 M - - - -254 M - - - -210 M - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

325 M 354 M 384 M 407 M 334 M 210 M 228 M - - - - 382 M - 458 M - 469 M - 473 M - 467 M - - - 501 M - - - 333 M - - - 331 M - - - 371 M - - - 167 M - - - - - - - - - - - - - - -

Cash and Cash Equivalents

61.5 M 59.8 M 143 M 149 M 137 M - 84.4 M - - - - 186 M - 248 M - 241 M - 261 M - 341 M - 397 M - 452 M - - - 256 M - - - 255 M - - - 342 M - - - 136 M - - - - - - - - - - - - - - -

Book Value

75.9 M 97.1 M 131 M 149 M 84.7 M 210 M 228 M - - - - 382 M - 458 M - 469 M - 473 M - 467 M - - - 501 M - - - 333 M - - - 331 M - - - 371 M - - - 167 M - - - - - - - - - - - - - - -

Total Shareholders Equity

75.9 M 97.1 M 131 M 149 M 84.7 M 76.1 M 96.6 M - - - - 236 M - 302 M - 309 M - 345 M - 355 M - 405 M - 450 M - - - 284 M - - - 273 M - - - 285 M - - - 72.3 M - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Cellectis S.A., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 3.13 - $ 651 M usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 34.45 4.74 % $ 927 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Forte Biosciences Forte Biosciences
FBRX
$ 20.31 1.2 % $ 263 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.19 4.46 % $ 5.57 B spainSpain
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 6.82 1.94 % $ 187 M israelIsrael
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
BioNTech SE BioNTech SE
BNTX
$ 90.36 2.93 % $ 21.8 B germanyGermany
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.62 -0.61 % $ 431 M britainBritain
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.71 -0.92 % $ 253 M israelIsrael
Anika Therapeutics Anika Therapeutics
ANIK
$ 15.14 2.16 % $ 217 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Incyte Corporation Incyte Corporation
INCY
$ 97.08 1.55 % $ 19 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.39 4.17 % $ 5.58 M israelIsrael
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.51 2.03 % $ 177 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 20.47 4.97 % $ 2.6 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA